Last reviewed · How we verify
YL-17231
At a glance
| Generic name | YL-17231 |
|---|---|
| Also known as | Pan-KRAS Inhibitor YL-17231 |
| Sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (PHASE1)
- A Study of YL-17231 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL-17231 CI brief — competitive landscape report
- YL-17231 updates RSS · CI watch RSS
- Shanghai YingLi Pharmaceutical Co. Ltd. portfolio CI